JA Morgan
JA Morgan
Dana Farber Cancer Institute
Verified email at
Cited by
Cited by
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
GD Demetri, AT van Oosterom, CR Garrett, ME Blackstein, MH Shah, ...
The Lancet 368 (9544), 1329-1338, 2006
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
TF Chu, MA Rupnick, R Kerkela, SM Dallabrida, D Zurakowski, L Nguyen, ...
The Lancet 370 (9604), 2011-2019, 2007
Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors
CP Raut, M Posner, J Desai, JA Morgan, S George, D Zahrieh, ...
Journal of Clinical Oncology 24 (15), 2325-2331, 2006
Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors
J Desai, L Yassa, E Marqusee, S George, MC Frates, MH Chen, ...
Annals of internal medicine 145 (9), 660-664, 2006
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure
S George, JY Blay, PG Casali, A Le Cesne, P Stephenson, SE Deprimo, ...
European journal of cancer 45 (11), 1959-1968, 2009
Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors
AJ Wagner, I Malinowska-Kolodziej, JA Morgan, W Qin, CDM Fletcher, ...
Journal of clinical oncology 28 (5), 835-840, 2010
Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas
S George, P Merriam, RG Maki, AD Van den Abbeele, JT Yap, T Akhurst, ...
Journal of Clinical Oncology 27 (19), 3154-3160, 2009
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial
S George, Q Wang, MC Heinrich, CL Corless, M Zhu, JE Butrynski, ...
Journal of Clinical Oncology 30 (19), 2401-2407, 2012
Breakpoints of the t (11; 18)(q21; q21) in mucosa-associated lymphoid tissue (MALT) lymphoma lie within or near the previously undescribed gene MALT1 in chromosome 18
JA Morgan, Y Yin, AD Borowsky, F Kuo, N Nourmand, JI Koontz, ...
Cancer research 59 (24), 6205-6213, 1999
A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib
TV Patel, JA Morgan, GD Demetri, S George, RG Maki, M Quigley, ...
Journal of the National Cancer Institute 100 (4), 282-284, 2008
Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: results of a phase 2 study
E Ben‐Ami, CM Barysauskas, S Solomon, K Tahlil, R Malley, M Hohos, ...
Cancer 123 (17), 3285-3290, 2017
Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors
R Quek, Q Wang, JA Morgan, GI Shapiro, JE Butrynski, N Ramaiya, ...
Clinical Cancer Research 17 (4), 871-879, 2011
Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors
GD Demetri, P Lo Russo, IRJ MacPherson, D Wang, JA Morgan, ...
Clinical Cancer Research 15 (19), 6232-6240, 2009
Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure
GD Demetri, MC Heinrich, JA Fletcher, CDM Fletcher, ...
Clinical Cancer Research 15 (18), 5902-5909, 2009
Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy
E Choy, JE Butrynski, DC Harmon, JA Morgan, S George, AJ Wagner, ...
BMC cancer 14, 1-6, 2014
SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic …
GD Demetri, J Desai, JA Fletcher, JA Morgan, CDM Fletcher, ...
Journal of Clinical Oncology 22 (14_suppl), 3001-3001, 2004
Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors
J Desai, S Shankar, MC Heinrich, JA Fletcher, CD Fletcher, J Manola, ...
Clinical Cancer Research 13 (18), 5398-5405, 2007
A phase I–II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors
P Schöffski, P Reichardt, JY Blay, H Dumez, JA Morgan, I Ray-Coquard, ...
Annals of oncology 21 (10), 1990-1998, 2010
Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST)
RG Maki, JA Fletcher, MC Heinrich, JA Morgan, S George, J Desai, ...
Journal of Clinical Oncology 23 (16_suppl), 9011-9011, 2005
Leiomyosarcoma of the inferior vena cava: survival after aggressive management
H Ito, JL Hornick, MM Bertagnolli, S George, JA Morgan, EH Baldini, ...
Annals of surgical oncology 14, 3534-3541, 2007
The system can't perform the operation now. Try again later.
Articles 1–20